Share this article
Share this article
ENGLEWOOD, Colo., Dec. 17, 2020 /PRNewswire/ Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today it has completed its Phase I clinical trial and has initiated the first steps for a global Phase II clinical trial for intravenous ( IV ) Ampion treatment in COVID-19 patients.
The Phase I study was a randomized, controlled study of adults hospitalized with severe COVID-19. The primary endpoint for the study was evaluated after a 5-day treatment period, and safety was followed for an additional 3 months. Half of the patients received IV Ampion plus the standard of care ( SOC ) for COVID-19 while the other half received SOC alone. The following highlights were observed:
COVID-19: MGC Pharma in talks with SEA countries for clinically backed supplement ASX-listed MGC Pharma is in talks with South East Asia (SEA) countries to make its clinically backed oral supplement trademarked ArtemiC commercially available for COVID-19 patients.
This is on the back of the company’s promising clinical findings on the oral spray supplement made up of artemisinin, curcumin, vitamin C, and Boswellia serrata.
The findings, announced yesterday (Dec 15), showed that all of the patients receiving the supplement plus standard care fully recovered in 15 days of follow up.
Involving 50 COVID-19 patients, the phase II double-blind, placebo-controlled clinical trial took place in three hospitals across Israel and India.
Dr Brian Creedon, Clinical Director, National Office of Clinical Audit
Continuing improvements for in-hospital mortality across major diagnoses
Rate of COPD in-hospital deaths rose by 12 per cent 2010 to 2019
A continuing fall in crude mortality trends across heart failure, pneumonia, acute myocardial infarction (AMI), and haemorrhagic stroke has been seen over a 10-year period
, according to findings of the fifth report by the National Audit of Hospital Mortality (NAHM) published today (December 15) by the National Office of Clinical Audit (NOCA). The report showed that there had been a continuing decrease in crude mortality trends in the four major diagnoses over the past 10 years. The rate for ischaemic stroke had decreased significantly also – until 2018 – but had seen an increase in mortality rates in 2019 compared with 2018.
Share:
Initial data show that treatment with ruxolitinib plus standard-of-care (SoC) did not prevent complications in patients with COVID-19 associated cytokine storm
Incyte (NASDAQ:INCY) today announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxolitinib (Jakafi
®), a JAK1/JAK2 inhibitor, plus standard-of-care (SoC) as a treatment for patients 12 years and older with COVID-19 associated cytokine storm did not meet its primary endpoint. Initial data show that there was no reduction in the proportion of patients receiving ruxolitinib plus SoC who experienced severe complications including death, respiratory failure requiring mechanical ventilation or admission to the intensive care unit (ICU) care by Day 29, compared to SoC treatment alone (12.0% vs. 11.8% [OR: 0.91 [95% CI: 0.48-1.73],
Novartis International AG: Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19
1
Detailed results will be submitted for publication to support scientific understanding of JAK inhibition in COVID-19 and inform ongoing research
Novartis commitment to address COVID-19 pandemic remains strong with multiple research collaboration initiatives ongoing
Basel, December 14, 2020 - Novartis today announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint
1. Initial data show there was no statistically significant reduction in the proportion of patients on ruxolitinib plus SoC therapy who experienced severe complications, including death, respiratory failure requiring mechanical ventilation or admission to the intensive care unit (ICU) by Day 29, compared to SoC alone